Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5551MR)

This product GTTS-WQ5551MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5551MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15849MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8849MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12892MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15877MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ15613MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ13516MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW